Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC
(Thomson Reuters ONE) -
Press Release
10 October 2017
Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel, immune-priming cancer treatment against a variety of solid
tumors, today announced the appointment of Sharon Longhurst as Head of
Chemistry, Manufacturing and Controls (CMC).
Dr. Longhurst comes to Immunicum with over 15 years in leading CMC efforts in
small and medium sized organizations. Most recently she served as Senior CMC
Manager at Akari Therapeutics in addition to having been a senior pharmaceutical
assessor for the Medicines & Healthcare Products Regulatory Agency (MHRA) in
London. Sharon will replace Karin Hoogendoorn, who has been extended the
opportunity to return to academia.
"Sharon's insights on advanced therapy manufacturing and CMC strategy will
support Immunicum's proposed plan to develop a commercially-ready CMC process
for our lead product candidate, ilixadencel," said Carlos de Sousa, CEO of
Immunicum. "We are happy for Karin's new career opportunity and we wish her all
the best."
"I am delighted to join Immunicum at this exciting stage of development for
ilixadencel," said Sharon Longhurst. "The potential for ilixadencel as an immune
system primer in multiple cancer indications is an exciting prospect that could
make a tremendous difference to those diagnosed and I very much look forward to
contributing to its further success in the clinic by bringing to the company my
CMC experience with biological products, in particular manufacturing and
regulatory experience with cell based therapy products."
Sharon Longhurst joins Immunicum from her previous position as Senior CMC
Manager at Akari Therapeutics, where she was responsible for all aspects of CMC
for an innovative biologic product, Coversin, including clinical supply and
distribution. Prior to that, Sharon spent 5 years as Principal Consultant of CMC
at Parexel Consulting. From 2005-2011, she was a Pharmaceutical Assessor at MHRA
in London in the biologics/biotechnology unit and provided national and EU
scientific advice for Advance Therapy Medicinal Products (ATMPs) for cell and
gene therapy. Sharon graduated from the University of Warwick, Coventry, UK with
a PhD in Virology.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info(at)immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir(at)immuicum.com
Investor and Media Relations EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: ir(at)immunicum.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the
development of allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the patient's own
immune system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the potential
to become a backbone component of modern cancer combination treatments in a
variety of solid tumor indications. Founded and based in Sweden, Immunicum is
publicly traded on the Nasdaq First North Premier. www.immunicum.com
-------------------------------------------------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 563001
Anzahl Zeichen: 4572
contact information:
Town:
Gothenburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 120 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunicum AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
